Pub. Date : 2016 May
PMID : 26966279
5 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
1 | Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein. | anacetrapib | cholesteryl ester transfer protein | Homo sapiens |
2 | Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein. | anacetrapib | cholesteryl ester transfer protein | Homo sapiens |
3 | OBJECTIVE: Anacetrapib (ANA), an inhibitor of cholesteryl ester transfer protein (CETP) activity, increases plasma concentrations of high-density lipoprotein cholesterol (HDL-C), apolipoprotein A-I (apoA)-I, apoA-II, and CETP. | anacetrapib | cholesteryl ester transfer protein | Homo sapiens |
4 | OBJECTIVE: Anacetrapib (ANA), an inhibitor of cholesteryl ester transfer protein (CETP) activity, increases plasma concentrations of high-density lipoprotein cholesterol (HDL-C), apolipoprotein A-I (apoA)-I, apoA-II, and CETP. | anacetrapib | cholesteryl ester transfer protein | Homo sapiens |
5 | OBJECTIVE: Anacetrapib (ANA), an inhibitor of cholesteryl ester transfer protein (CETP) activity, increases plasma concentrations of high-density lipoprotein cholesterol (HDL-C), apolipoprotein A-I (apoA)-I, apoA-II, and CETP. | anacetrapib | cholesteryl ester transfer protein | Homo sapiens |